A designed microbial consortium may protect against locomotor decline in a fly model of Parkinson's disease neurodegeneration.
Evidence
This preclinical Drosophila melanogaster study used genome-scale metabolic modeling, bioreactors, female PD flies, head metabolomics, and microbiome profiling to test a -producing consortium.
Caveat
The results come from a fly model with female flies and metabolomic proxies, so they do not show therapeutic benefit in human Parkinson's disease.
Simplified
The enables communication between the central nervous system and the gut, with certain microbial metabolites influencing neurodegeneration. Using genome-scale metabolic modeling, we designed and tested a synthetic microbial consortium with predicted capacity to produce and other neurometabolites in a Drosophila melanogaster model of neurodegeneration of Parkinson's Disease (PD). The consortium (Levilactobacillus brevis, Lacticaseibacillus paracasei, Bacteroides thetaiotaomicron) produced GABA in bioreactors. Female PD flies receiving the consortium exhibited protection from locomotor impairment at 10 and 25 days upon consortium administration. Head metabolomics revealed partial restoration of PD-associated alterations in energy balance, amino acid and neurotransmitter metabolism, and disease-related biomarkers. Early administration increased microbiome diversity and Lactobacillus abundance. These findings suggest that rationally designed microbial consortia targeting neurometabolite production can modulate brain physiology and confer neuroprotection, supporting their potential for microbiome-based interventions in neurodegenerative disease.
Key numbers
5.146
Increase in gut microbiome diversity
Measured using Shannon's diversity index across experimental groups.
3 g/L
production in vitro
Measured in two of the six consortia during fermentation.
n per group=60
Survival increase associated with
Evaluated through survival assays comparing treated and untreated groups.
Full Text
We can’t show the full text here under this license.
